NASDAQ$BNGO
BioNano Genomics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results with revenue growth and progress on ELEVATE! milestones.
Bionano Genomics reported a 55% year-over-year revenue growth in Q3 2022, reaching $7.2 million, the highest quarterly revenue to date. The company is on track to achieve all 2022 ELEVATE! milestones and maintains a strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities.
- Total revenue for Q3 2022 was $7.2 million, representing the highest quarterly revenue to date.
- The installed base of Saphyr systems grew by 21 to 217 as of the end of Q3 2022, an 11% increase compared to Q2 2022.
- Sold 3,975 nanochannel array flowcells during Q3 2022, a record for the company.
- Bionano Laboratories launched, combining OGM data services with clinical testing services.
Headline financials
Revenue & EPS history
BioNano · Revenue · Quarterly
$7.22M
Revenue by segment
BioNano · $7.22M total across 2 segments · Q3 2022
- Service and Other Revenue$3.62M+166.8%50.1%
- Product Revenue$3.61M+9.3%49.9%
Forward guidance
The company expects revenues for the fourth quarter to be in the range of $7.5 million to $8 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-3.3%
Avg return
Earnings day
-6.2%
Avg return
5 days after
-8.0%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+15.5%
Q4 2018
Best reaction
-29.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.8% | -9.5% | — | |
| Q4 2025 | +0.9% | -20.5% | -17.1% | |
| Q3 2025 | +2.8% | +4.8% | +10.2% | |
| Q1 2025 | +2.9% | +0.8% | -2.4% | |
| Q4 2024 | +11.1% | +8.6% | +43.4% | |
| Q3 2024 | -3.4% | -11.5% | -7.7% | |
| Q2 2024 | -21.5% | -23.5% | -13.7% | |
| Q1 2024 | +2.7% | +7.3% | -9.4% | |
| Q4 2023 | +0.0% | -5.8% | -18.2% | |
| Q3 2023 | -7.0% | -10.5% | +2.8% | |
| Q2 2023 | -0.2% | -13.9% | -15.7% | |
| Q1 2023 | +6.9% | -9.6% | +0.0% | |
| Q4 2022 | -8.4% | -5.3% | -19.8% | |
| Q3 2022 | +2.7% | +2.2% | -6.3% | |
| Q2 2022 | +6.6% | +0.0% | +2.2% | |
| Q1 2022 | -16.1% | -24.2% | -10.8% | |
| Q4 2021 | +1.4% | -10.7% | +20.6% | |
| Q3 2021 | -9.8% | -13.7% | -44.4% | |
| Q2 2021 | +5.4% | +4.4% | -1.0% | |
| Q1 2021 | +13.9% | +22.8% | +59.9% | |
| Q4 2020 | -17.9% | -14.4% | -34.1% | |
| Q3 2020 | -7.4% | -5.4% | -10.7% | |
| Q2 2020 | -8.4% | -6.5% | -32.5% | |
| Q1 2020 | -8.4% | -11.8% | +21.6% | |
| Q4 2019 | -29.8% | -30.3% | -74.3% | |
| Q3 2019 | -2.1% | +17.8% | +24.4% | |
| Q2 2019 | -14.4% | -11.3% | -50.5% | |
| Q1 2019 | -11.3% | -17.0% | -28.1% | |
| Q4 2018 | +15.5% | +7.4% | -8.1% | |
| Q3 2018 | -6.0% | -5.7% | -11.9% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro